Clinical Trial Update: Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis [NA]

View source ↗

Summary

A clinical trial at Beijing Children's Hospital is evaluating letermovir prophylaxis in pediatric patients with EBV-associated T/NK-cell Lymphoproliferative Dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-associated Nk-cell Lymphoproliferative Diseases
• Ebv-related Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Beijing Children's Hospital | Conditions: EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis | NA | Status: RECRUITING